Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck & Co., Inc. : Lawsuit Claims Merck Overstated Mumps Vaccine Effectiveness

share with twitter share with LinkedIn share with facebook
06/22/2012 | 01:32pm EDT
   By Jon Kamp 

Two former Merck & Co. Inc. (MRK) employees have sued the company in federal court alleging Merck overstated the effectiveness of a mumps vaccine for which the U.S. government paid hundreds of millions of dollars.

Merck--which stressed that none of these allegations relate to the safety of its product--said the lawsuit is "completely without merit", and that it plans to "vigorously defend itself." The Whitehouse Station, N.J., drug maker also noted that the U.S. Department of Justice has thus far declined to participate in the case after its own two-year probe.

Mumps is a contagious disease that causes symptoms like fever, headache and swollen salivary glands. It was a common illness for kids and young adults before childhood vaccinations became common decades ago, according to the Centers for Disease Control and Prevention, although there were outbreaks in 2006 and 2009. The agency says vaccines are the best way to prevent mumps.

Merck introduced the first vaccine 45 years ago, and since the 1970s it's been part of a combination product that also immunizes children against rubella and measles. According to the lawsuit--filed by former Merck virologists Stephen Krahling and Joan Wlochowski--the company allegedly defrauded the U.S. for more than a decade by hiding the fact the vaccine had become less effective.

As a result, the former employees say the government has long paid for a product that doesn't live up to Merck's claims. The lawsuit seeks a judgment against Merck equal to three times the damages suffered by the U.S., plus the maximum allowable award for the former employees under federal whistleblower laws.

The suit was first filed in 2010 in the U.S. District Court for the Eastern District of Pennsylvania. It was unsealed Thursday after the government declined to get involved in the case.

Merck confirmed Krahling and Wlochowski were former employees, but it said they haven't worked at the company for a decade.

"It's important to understand that none of the allegations in the complaint relate to the safety of M-M-R II"--the vaccine in question--"and we remain confident that M-M-R II helps protect against measles, mumps and rubella as described in the labeling for the vaccine," Merck said in a statement.

"M-M-R II continues to be recommended for routine administration to children by public health authorities around the world, including the U.S. Centers for Disease Control and Prevention and the U.S. Food and Drug Administration," the company said.

Merck doesn't specifically break out sales for the vaccine, but the company reported combined U.S. sales of $1.1 billion last year for that product and two other childhood vaccines. Merck shares recently traded up 1.9% to $40.19 and have risen 6.6% this year.

Write to Jon Kamp at jon.kamp@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
BEST INC. 3.23% 4.8 Delayed Quote.-13.67%
MERCK & CO., INC. -1.58% 76.69 Delayed Quote.-15.68%
share with twitter share with LinkedIn share with facebook
Latest news on MERCK & CO., INC.
07/09MERCK : Animal Health Gets FDA Approval of Bravecto Monthly Chews
07/09MERCK : Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Month..
07/09MERCK : Announces Appointment of Organon and Co. General Counsel
07/09EISAI : and Merck Receive Complete Response Letter for LENVIMA plus KEYTRUDA Com..
07/09MERCK : AstraZeneca and Merck - LYNPARZA Approved in the EU for Germline BRCA-mu..
07/09MERCK : Gets FDA Priority Review of Keytruda in Classical Hodgkin Lymphoma
07/09MERCK : FDA Grants Priority Review to Merck's Supplemental Biologics License App..
07/08MERCK : Announces Appointment of Organon & Co. General Counsel
07/08AstraZeneca, Merck Get Europe OK for Lynparza in Pancreatic Cancer
07/08MERCK : LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metast..
More news
Financials (USD)
Sales 2020 47 254 M - -
Net income 2020 11 135 M - -
Net Debt 2020 14 029 M - -
P/E ratio 2020 17,5x
Yield 2020 3,12%
Capitalization 194 B 194 B -
EV / Sales 2019
EV / Sales 2020 4,39x
Nbr of Employees 71 000
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 20
Average target price 92,84 $
Last Close Price 76,69 $
Spread / Highest target 39,5%
Spread / Average Target 21,1%
Spread / Lowest Target 5,62%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-15.68%193 573
JOHNSON & JOHNSON-1.78%377 458
ROCHE HOLDING AG5.27%299 642
NOVARTIS AG-10.23%193 644
PFIZER, INC.-14.60%187 476
ABBVIE INC.10.62%174 965